Trials / Unknown
UnknownNCT02280278
Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy
The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 550 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
We hypothesize through this randomized, prospective, single center adjuvant study, that cytokine-induced killer cell in patients with stage III colon cancer can improve survival in this patient population over control. Stage III colon cancer patients can benefit most from adjuvant chemotherapy, but the 5 year survival rate is still around 60%. We wish CIK cell therapy can improve the survival rate of stage III colon cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Radical surgery | |
| DRUG | Adjuvant chemotherapy | |
| BIOLOGICAL | Cytokine-induced killer cell immunotherapy |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2019-10-01
- First posted
- 2014-10-31
- Last updated
- 2014-11-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02280278. Inclusion in this directory is not an endorsement.